<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01997905</url>
  </required_header>
  <id_info>
    <org_study_id>CP2011-2</org_study_id>
    <nct_id>NCT01997905</nct_id>
  </id_info>
  <brief_title>Stroke Feasibility Study</brief_title>
  <official_title>Feasibility Clinical Investigation of a Minimally Invasive Surgically Deployed AtriCure AtriClip Left Atrial Appendage Exclusion System for Stroke Prophylaxis in Patients With Non-Valvular Atrial Fibrillation and in Whom Long Term Oral Anticoagulation Therapy is Medically Contraindicated</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AtriCure, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AtriCure, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a feasibility study to assess the safety and efficacy of the AtriCure AtriClip when
      placed via Minimally Invasive Surgical Deployment to the Left Atrial Appendage. The purpose
      is for evaluation of Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation who
      are unable to take Oral Anticoagulants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Serious Adverse Events Within 30 Days Post-Index Procedure</measure>
    <time_frame>30 days post-index procedure</time_frame>
    <description>The primary safety endpoint consists of the following serious adverse events within 30 days post-index procedure (unless otherwise noted), as adjudicated by Independent Physician Adjudicator:
Serious Injury to the cardiac structure or other body structure deemed to be related to the delivery or placement of the Clip
Cardiac-Related Death, Myocardial Infarction, or Ischemic Stroke
Major bleeding (defined as requiring re-operation and/or transfusion (&gt; 2 U packed red blood cells (PRBC)) within any 24 hour period during the first 2 days post-index procedure or at any time point if attributed to the device/index procedure).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite Left Atrial Appendage Placement and Exclusion Success</measure>
    <time_frame>Immediate to 3-months post-index procedure</time_frame>
    <description>Primary Efficacy endpoint is a success/failure endpoint with success requiring all of the following:
Patient Technical Success: The ability to successfully implant an AtriClip device at the LAA in a patient.
Intra-Procedural Complete Exclusion of the LAA: The complete exclusion of the LAA defined by lack of fluid communication (&lt;3 mm residual communication with LAA and &lt;10 mm residual pocket) between the LA and LAA, assessed intra-procedurally by TEE.
3 Month Follow-Up Complete Exclusion of the LAA: The complete exclusion of the LAA defined by lack of fluid communication (&lt;3 mm residual communication with LAA and &lt; 10mm residual pocket) between the LA and LAA at &gt;=3 month TEE or CTA evaluation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Stroke and Non-CNS Systemic Embolism</measure>
    <time_frame>3 months and 6 months post-index procedure</time_frame>
    <description>The secondary efficacy endpoints will be a composite of the following events within 3 months and 6 months post-index procedure:
Stroke (ischemic )
Non-CNS (Central Nervous System) systemic embolism.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Device or Procedure Related Adverse Event Rate</measure>
    <time_frame>3 month and 6 month post-index procedure</time_frame>
    <description>Overall Serious Device or Procedure Related Adverse Event Rate: Incidence of all serious device or procedure related adverse events observed through the 3 month and 6 month follow-up assessments as adjudicated by Independent Physician Adjudicator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Serious Adverse Event Rate</measure>
    <time_frame>3 month and 6 month Post Index Procedure</time_frame>
    <description>Overall Serious Adverse Event Rate: Incidence of all serious adverse events, regardless of attribution, observed through the 3 month and 6 month follow-up assessments, as adjudicated by Independent Physician Adjudicator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Adverse Event Rate</measure>
    <time_frame>3 month and 6 month post-index procedure</time_frame>
    <description>Overall Adverse Event Rate: Incidence of all device and procedure related adverse events and any neurological related AEs, regardless of attribution, observed through the 3 month and 6 month follow-up assessments, as adjudicated by Independent Physician Adjudicator.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>AFib</condition>
  <arm_group>
    <arm_group_label>AtriClip LAA Exclusion Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AtriClip delivered via minimally invasive surgical procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AtriClip LAA Exclusion Device</intervention_name>
    <arm_group_label>AtriClip LAA Exclusion Device</arm_group_label>
    <other_name>LAAØ</other_name>
    <other_name>PRO1</other_name>
    <other_name>AtriClip™ LAA Exclusion System</other_name>
    <other_name>AtriClip™ LAA Exclusion System w/ preloaded Gillinov-Cosgrove™ Clip</other_name>
    <other_name>AtriClip LAA Exclusion System and Delivery System (LAAØ)</other_name>
    <other_name>AtriClip LAA Exclusion System and Delivery System (PRO1)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient is ≥ 18 years and ≤ 80 years of age.

          2. Patient has electrocardiographically confirmed non-valvular atrial fibrillation
             (paroxysmal, persistent, or longstanding persistent AF).

          3. CHADS2 or CHA2DS2VASc score ≥2.

          4. Patient has medical contraindication to long term anticoagulant therapy (OAC), defined
             as one or more of the following:

               -  history of intracranial bleeding (e.g. due to amyloid angiopathy or other
                  condition) which renders patient unsafe for OAC;

               -  history of gastrointestinal, genitourinary, or respiratory tract bleeding due to
                  permanent condition which renders patient unsafe for OAC;

               -  HAS-BLED Score ≥ 3.

          5. Patient is considered an acceptable surgical candidate, including use of general
             anesthesia.

          6. Female patients must be of non-child bearing potential, or have a negative pregnancy
             test within 7 days prior to index procedure.

        Exclusion Criteria:

          1. Stroke within 30 days, or TIA within 3 days, respectively, prior to index procedure.

          2. Documented medical history of any penetrating trauma to thorax, or blunt trauma to
             thorax which resulted in a left pneumothorax or left hemothorax.

          3. Myocardial infarction within 60 days prior to index procedure.

          4. NYHA Class IV heart failure.

          5. Ejection fraction &lt; 40% (based on baseline transthoracic echocardiography (TTE)).

          6. Prior attempted obliteration of left atrial appendage (percutaneous or open cardiac
             surgery).

          7. Previous catheter ablation with perforation or complication.

          8. Prior open cardiac surgery, or percutaneous coronary intervention with associated
             unintended cardiac perforation, or pericardial adhesions are suspected.

          9. History of pericarditis or pericardiocentesis.

         10. Active infection, septicemia, or fever of unknown origin.

         11. Concomitant elective surgical procedure (in addition to AtriClip placement) at the
             time of index procedure.

         12. Planned atrial arrhythmia ablation procedure within six months following index
             procedure.

         13. Underlying structural heart disease requiring planned surgical treatment within six
             months following the index procedure.

         14. Cardiac or thoracic surgical procedure within the thirty days prior to index
             procedure.

         15. Anticoagulation therapy for other medical condition (i.e. deep vein thrombosis) is
             required.

         16. Patient unable to discontinue thienopyridines (e.g. clopidogrel) or non-ASA
             antiplatelet agents 4 days pre-operatively and abstain for at least 2 days
             post-operatively.

         17. Renal Failure as defined by creatinine &gt; 2.0 mg/dl (&gt; 152.5 umol/L) and/or need for
             dialysis.

         18. Known carotid artery diameter stenosis greater than 80%.

         19. Patient has symptomatic or high-grade carotid disease (&gt;70% bilaterally).

         20. Patient unable or unwilling to undergo transesophageal echocardiography (TEE).

         21. Presence of thrombus in the left atrium or LAA, as determined by baseline TTE or
             Computed Tomography Angiogram (CTA).

         22. Documented history of thrombophilic disorder, with diagnosis established via previous
             objective testing (e.g. familial screening for thrombophilia).

         23. Moderate to Severe Chronic Obstructive Pulmonary Disease (FEV1 or VC&lt;70% predicted) or
             intolerant of single lung ventilation.

         24. History of Hypercoagulopathy

         25. Body Mass Index (BMI) &gt; 35.

         26. Other medical illness or comorbidity that may cause non-compliance with the protocol,
             confound data interpretation (e.g. severe dementia), or limited life expectancy (i.e.
             &lt; 3 months).

         27. Enrolled in another investigational device or drug study at the time of enrollment and
             during the course of the study.

         28. Psychiatric disorder which in the judgment of the investigator could interfere with
             informed consent, completion of tests, therapy, or follow-up.

         29. Patient is pregnant or intends to become pregnant within 6 months post-index
             procedure.

        Intraoperative Exclusion Criteria

          1. Left atrial appendage width &lt; 29mm or &gt; 50mm, based on TEE imaging.

          2. Presence of thrombus in the left atrium or LAA based on TEE imaging.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Basel Ramlawi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Methodist Hospital Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Helena Hospital</name>
      <address>
        <city>St. Helena</city>
        <state>California</state>
        <zip>94574</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franciscan St. Francis Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aspirus</name>
      <address>
        <city>Wausau</city>
        <state>Wisconsin</state>
        <zip>54401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2013</study_first_submitted>
  <study_first_submitted_qc>November 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2013</study_first_posted>
  <results_first_submitted>January 27, 2016</results_first_submitted>
  <results_first_submitted_qc>August 30, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 21, 2016</results_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Left Atrial Appendage</keyword>
  <keyword>LAA</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>AFib</keyword>
  <keyword>AF</keyword>
  <keyword>IRB approved</keyword>
  <keyword>clinical</keyword>
  <keyword>Stroke</keyword>
  <keyword>TIA</keyword>
  <keyword>contraindication to oral anticoagulation therapy</keyword>
  <keyword>Arrhythmias, Cardiac</keyword>
  <keyword>OAC</keyword>
  <keyword>trial</keyword>
  <keyword>study</keyword>
  <keyword>LAA occlusion</keyword>
  <keyword>occluded</keyword>
  <keyword>prevent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first subject was enrolled (defined as signed informed consent) on March 25, 2014. The last subject completed their final visit as of July 31, 2015. A total of 13 subjects were enrolled from 4 sites. Of the 13 enrolled subjects, 10 were treated (defined as attempted surgery) with the investigational device.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>AtriClip LAA Exclusion Device</title>
          <description>AtriClip delivered via minimally invasive surgical procedure
AtriClip LAA Exclusion Device</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Baseline Completed</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AtriClip LAA Exclusion Device</title>
          <description>AtriClip delivered via minimally invasive surgical procedure
AtriClip LAA Exclusion Device</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72" spread="8.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NYHA Functional Class</title>
          <description>Doctors usually classify patients' heart failure according to the severity of their symptoms. The table below describes the most commonly used classification system, the New York Heart Association (NYHA) Functional Classification. It places patients in one of four categories based on how much they are limited during physical activity(http://www.heart.org/HEARTORG/Conditions/HeartFailure/AboutHeartFailure/Classes-of-Heart-Failure_UCM_306328_Article.jsp#.V8WM3md4epo). The higher the category, the more severe the symptoms.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>I (No symptoms and no limitations)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>II (Mild symptoms and slight limitation)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>III (Marked limitation)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IV (Severe limitations)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Heart Block</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CHADS2 Score</title>
          <description>CHADS2 is based on the following: Congestive Heart Failure, Hypertension, Age (75 years or older), Diabetes Mellitus, and Stroke (history of stroke or transient ischemic attack). For each factor that is present, the patient receives one point for a total of 6 points. The higher the CHADS2 score the higher the stroke risk.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.9" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CHA2DSVAS Score</title>
          <description>CHA2DS2-VASc included additional 'stroke risk modifier' risk factors to the CHADS2. CHA2DS2-VASc score was extended to include: age 65-74, female gender and vascular disease. In the CHA2DS2-VASc score, 'age 75 and above' also has extra weight, with 2 points. The maximum CHA2DS2-VASc score is 9 (for age, either the patient is ≥75 years and gets two points, is between 65-74 and gets one point, or is under 65 and get no point). The higher the CHA2DS2-VASc score, the higher the stroke risk.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.6" spread="0.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HAS-BLED Score</title>
          <description>A risk score to estimate the one year risk of major bleeding (i.e. intracranial, requiring hospitalization, hemoglobin decrease&gt; 2g/L, and/or transfusion) in patients with atrial fibrillation. HAS-BLED score can range from 0 to 9 points, depending upon the number of risk factors for a given patient. HAS-BLED includes the following factors: Hypertension, Abnormal Kidney and/or Liver Function, Stroke (previous history of stroke, especially deep brain (lacunar) stroke), Bleeding, Labile INR, Elderly (&gt;65 years) and Drugs and/or alcohol. The higher the score, the higher the risk of bleeding.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.6" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Serious Adverse Events Within 30 Days Post-Index Procedure</title>
        <description>The primary safety endpoint consists of the following serious adverse events within 30 days post-index procedure (unless otherwise noted), as adjudicated by Independent Physician Adjudicator:
Serious Injury to the cardiac structure or other body structure deemed to be related to the delivery or placement of the Clip
Cardiac-Related Death, Myocardial Infarction, or Ischemic Stroke
Major bleeding (defined as requiring re-operation and/or transfusion (&gt; 2 U packed red blood cells (PRBC)) within any 24 hour period during the first 2 days post-index procedure or at any time point if attributed to the device/index procedure).</description>
        <time_frame>30 days post-index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AtriClip LAA Exclusion Device</title>
            <description>AtriClip delivered via minimally invasive surgical procedure
AtriClip LAA Exclusion Device</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Serious Adverse Events Within 30 Days Post-Index Procedure</title>
          <description>The primary safety endpoint consists of the following serious adverse events within 30 days post-index procedure (unless otherwise noted), as adjudicated by Independent Physician Adjudicator:
Serious Injury to the cardiac structure or other body structure deemed to be related to the delivery or placement of the Clip
Cardiac-Related Death, Myocardial Infarction, or Ischemic Stroke
Major bleeding (defined as requiring re-operation and/or transfusion (&gt; 2 U packed red blood cells (PRBC)) within any 24 hour period during the first 2 days post-index procedure or at any time point if attributed to the device/index procedure).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Composite Left Atrial Appendage Placement and Exclusion Success</title>
        <description>Primary Efficacy endpoint is a success/failure endpoint with success requiring all of the following:
Patient Technical Success: The ability to successfully implant an AtriClip device at the LAA in a patient.
Intra-Procedural Complete Exclusion of the LAA: The complete exclusion of the LAA defined by lack of fluid communication (&lt;3 mm residual communication with LAA and &lt;10 mm residual pocket) between the LA and LAA, assessed intra-procedurally by TEE.
3 Month Follow-Up Complete Exclusion of the LAA: The complete exclusion of the LAA defined by lack of fluid communication (&lt;3 mm residual communication with LAA and &lt; 10mm residual pocket) between the LA and LAA at &gt;=3 month TEE or CTA evaluation.</description>
        <time_frame>Immediate to 3-months post-index procedure</time_frame>
        <population>Ten (10) patients were treated, however the AtriClip® device was not implanted in one (1) patient.</population>
        <group_list>
          <group group_id="O1">
            <title>AtriClip LAA Exclusion Device</title>
            <description>AtriClip delivered via minimally invasive surgical procedure
AtriClip LAA Exclusion Device</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Left Atrial Appendage Placement and Exclusion Success</title>
          <description>Primary Efficacy endpoint is a success/failure endpoint with success requiring all of the following:
Patient Technical Success: The ability to successfully implant an AtriClip device at the LAA in a patient.
Intra-Procedural Complete Exclusion of the LAA: The complete exclusion of the LAA defined by lack of fluid communication (&lt;3 mm residual communication with LAA and &lt;10 mm residual pocket) between the LA and LAA, assessed intra-procedurally by TEE.
3 Month Follow-Up Complete Exclusion of the LAA: The complete exclusion of the LAA defined by lack of fluid communication (&lt;3 mm residual communication with LAA and &lt; 10mm residual pocket) between the LA and LAA at &gt;=3 month TEE or CTA evaluation.</description>
          <population>Ten (10) patients were treated, however the AtriClip® device was not implanted in one (1) patient.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Stroke and Non-CNS Systemic Embolism</title>
        <description>The secondary efficacy endpoints will be a composite of the following events within 3 months and 6 months post-index procedure:
Stroke (ischemic )
Non-CNS (Central Nervous System) systemic embolism.</description>
        <time_frame>3 months and 6 months post-index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AtriClip LAA Exclusion Device</title>
            <description>AtriClip delivered via minimally invasive surgical procedure
AtriClip LAA Exclusion Device</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Stroke and Non-CNS Systemic Embolism</title>
          <description>The secondary efficacy endpoints will be a composite of the following events within 3 months and 6 months post-index procedure:
Stroke (ischemic )
Non-CNS (Central Nervous System) systemic embolism.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serious Device or Procedure Related Adverse Event Rate</title>
        <description>Overall Serious Device or Procedure Related Adverse Event Rate: Incidence of all serious device or procedure related adverse events observed through the 3 month and 6 month follow-up assessments as adjudicated by Independent Physician Adjudicator.</description>
        <time_frame>3 month and 6 month post-index procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AtriClip LAA Exclusion Device</title>
            <description>AtriClip delivered via minimally invasive surgical procedure
AtriClip LAA Exclusion Device</description>
          </group>
        </group_list>
        <measure>
          <title>Serious Device or Procedure Related Adverse Event Rate</title>
          <description>Overall Serious Device or Procedure Related Adverse Event Rate: Incidence of all serious device or procedure related adverse events observed through the 3 month and 6 month follow-up assessments as adjudicated by Independent Physician Adjudicator.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Serious Adverse Event Rate</title>
        <description>Overall Serious Adverse Event Rate: Incidence of all serious adverse events, regardless of attribution, observed through the 3 month and 6 month follow-up assessments, as adjudicated by Independent Physician Adjudicator.</description>
        <time_frame>3 month and 6 month Post Index Procedure</time_frame>
        <population>All treated patients.</population>
        <group_list>
          <group group_id="O1">
            <title>AtriClip LAA Exclusion Device</title>
            <description>AtriClip delivered via minimally invasive surgical procedure
AtriClip LAA Exclusion Device</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Serious Adverse Event Rate</title>
          <description>Overall Serious Adverse Event Rate: Incidence of all serious adverse events, regardless of attribution, observed through the 3 month and 6 month follow-up assessments, as adjudicated by Independent Physician Adjudicator.</description>
          <population>All treated patients.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cardiac Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections and Infestations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neoplasms Benign (Carcinoid Tumor Pulmonary)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Adverse Event Rate</title>
        <description>Overall Adverse Event Rate: Incidence of all device and procedure related adverse events and any neurological related AEs, regardless of attribution, observed through the 3 month and 6 month follow-up assessments, as adjudicated by Independent Physician Adjudicator.</description>
        <time_frame>3 month and 6 month post-index procedure</time_frame>
        <population>All treated patients.</population>
        <group_list>
          <group group_id="O1">
            <title>AtriClip LAA Exclusion Device</title>
            <description>AtriClip delivered via minimally invasive surgical procedure
AtriClip LAA Exclusion Device</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Adverse Event Rate</title>
          <description>Overall Adverse Event Rate: Incidence of all device and procedure related adverse events and any neurological related AEs, regardless of attribution, observed through the 3 month and 6 month follow-up assessments, as adjudicated by Independent Physician Adjudicator.</description>
          <population>All treated patients.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood and Lymphatic System Disorders (Anaemia)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eye Disorder (Cataract)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immune Disorder (Seasonal Allergy)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Infections and Infestations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injury (Accident at Home, Radius Fracture)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Investigations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolism and Nutrition Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neoplasms Benign (Carcinoid Tumor Pulmonary)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nervous System Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Psychiatric Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal and Urinary Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgical and Medical Procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Incidence of Serious Adverse Events reported during the study</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AtriClip LAA Exclusion Device</title>
          <description>AtriClip delivered via minimally invasive surgical procedure
AtriClip LAA Exclusion Device</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pnemonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Carinoid tumor pulmonary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular Deconditioning</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diastolic Dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Sick Sinus Sundrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Rectal Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal Allergy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident at Home</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Radius Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Biopsy Lung Abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Troponin Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Electrolyte Imbalance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Carinoid Tumor Pulmonary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Altered State of Consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic Nephropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Renal Colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Pulmonary Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Respiatory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cataract Operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Basel Ramlawi, MD</name_or_title>
      <organization>Methodist Hospital Houston</organization>
      <phone>713-441-5200</phone>
      <email>basel.ramlawi@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

